OBJECTIVE: To explore dose-response effects of lisdexamfetamine dimesylate (LDX) treatment for ADHD. METHOD: This was a 4-week, randomized, double-blinded, placebo-controlled, parallel-group, forced-dose titration study in adult participants, aged 18 to 55 years, meeting Diagnostic and Statistical Manual of Mental Disorders (4th ed., text rev.) criteria for ADHD. RESULTS: Nearly all participants assigned to an LDX dose achieved their assigned dose with the exception of about 4% of participants assigned to the 50 mg or 14% assigned to the 70 mg doses. Higher doses of LDX led to greater improvements in ADHD-rating scale scores, independent of prior pharmacotherapy. This was evident for both inattentive and hyperactive-impulsive symptoms. The authors found some evidence for an interaction between LDX dose and baseline severity of ADHD symptoms. CONCLUSION: For LDX doses between 30 and 70 mg/d, the dose-response efficacy effect for LDX is not affected by prior pharmacotherapy, but patients with a greater severity of illness may benefit more from higher doses, especially for hyperactive-impulsive symptoms. The results do not provide information about doses above 70 mg/d, which is the maximum approved dose of LDX and the highest dose studied in ADHD clinical trials.
RCT Entities:
OBJECTIVE: To explore dose-response effects of lisdexamfetamine dimesylate (LDX) treatment for ADHD. METHOD: This was a 4-week, randomized, double-blinded, placebo-controlled, parallel-group, forced-dose titration study in adult participants, aged 18 to 55 years, meeting Diagnostic and Statistical Manual of Mental Disorders (4th ed., text rev.) criteria for ADHD. RESULTS: Nearly all participants assigned to an LDX dose achieved their assigned dose with the exception of about 4% of participants assigned to the 50 mg or 14% assigned to the 70 mg doses. Higher doses of LDX led to greater improvements in ADHD-rating scale scores, independent of prior pharmacotherapy. This was evident for both inattentive and hyperactive-impulsive symptoms. The authors found some evidence for an interaction between LDX dose and baseline severity of ADHD symptoms. CONCLUSION: For LDX doses between 30 and 70 mg/d, the dose-response efficacy effect for LDX is not affected by prior pharmacotherapy, but patients with a greater severity of illness may benefit more from higher doses, especially for hyperactive-impulsive symptoms. The results do not provide information about doses above 70 mg/d, which is the maximum approved dose of LDX and the highest dose studied in ADHD clinical trials.
Authors: L L Greenhill; S Pliszka; M K Dulcan; W Bernet; V Arnold; J Beitchman; R S Benson; O Bukstein; J Kinlan; J McClellan; D Rue; J A Shaw; S Stock; K Kroeger Journal: J Am Acad Child Adolesc Psychiatry Date: 2001-11 Impact factor: 8.829
Authors: M L Wolraich; L L Greenhill; W Pelham; J Swanson; T Wilens; D Palumbo; M Atkins; K McBurnett; O Bukstein; G August Journal: Pediatrics Date: 2001-10 Impact factor: 7.124
Authors: Narong Maneeton; Benchalak Maneeton; Sirijit Suttajit; Jirayu Reungyos; Manit Srisurapanont; Stephen D Martin Journal: Drug Des Devel Ther Date: 2014-10-03 Impact factor: 4.162
Authors: Lisa L Weyandt; Danielle R Oster; Marisa E Marraccini; Bergljot Gyda Gudmundsdottir; Bailey A Munro; Brynheld Martinez Zavras; Ben Kuhar Journal: Psychol Res Behav Manag Date: 2014-09-09